Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
Racial Disparities in Primary Therapy for Newly Diagnosed Psoriasis Patients
July 2023 | Volume 22 | Issue 7 | Features | 715 | Copyright © July 2023
Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities
June 2023 | Volume 22 | Issue 6 | Original Article | 621 | Copyright © June 2023
Psoriasis is associated with multiple comorbidities. In this retrospective cohort analysis, we compared the comorbidities in patients who received biologic treatments with those who received conventio...
Read MoreCross-Sectional Study of Psoriasis, Atopic Dermatitis, Rosacea, and Alopecia Areata Suggests Association With Cardiovascular Diseases
June 2023 | Volume 22 | Issue 6 | Original Article | 576 | Copyright © June 2023
Background: A growing body of evidence suggests that several inflammatory skin diseases (ISDs) are associated with systemic inflammation and cardiovascular disease (CVDs)....
Read MorePatient Preferences in Topical Psoriasis Treatment
April 2023 | Volume 22 | Issue 4 | Original Article | 326 | Copyright © April 2023
Background: Psoriasis is a common inflammatory skin condition that varies in severity. Most patients have limited disease amenable to topical treatment; however, poor treatment a...
Read MoreBrodalumab: 4-Year US Pharmacovigilance Report
April 2023 | Volume 22 | Issue 4 | Features | 419 | Copyright © April 2023
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. B...
Read MoreEvaluating Sentiment, Engagement, and Perception of Biologics Among Patients with Psoriasis and Psoriatic Arthritis on Reddit
March 2023 | Volume 22 | Issue 3 | Features | 306 | Copyright © March 2023
Background: Limited analyses of social media content among psoriasis (PsO) and psoriatic arthritis (PsA) patients exist. These patients may turn to social media to gain insight i...
Read MoreBreaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene
March 2023 | Volume 22 | Issue 3 | Original Article | 247 | Copyright © March 2023
Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs. Topical steroids and tazarotene are both options fo...
Read MorePatient Preference for Calcipotriene and Betamethasone Dipropionate Cream Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study
March 2023 | Volume 22 | Issue 3 | Original Article | 271 | Copyright © March 2023
Background: The well-established sequential use of topical calcipotriene and topical betamethasone dipropionate in combination has been shown to provide greater benefit than eith...
Read MoreMeeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion
February 2023 | Volume 22 | Issue 2 | Original Article | 132 | Copyright © February 2023
Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for pl...
Read MoreAn Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis
February 2023 | Volume 22 | Issue 2 | Features | 223 | Copyright © February 2023
Copy: Palmoplantar psoriasis is a chronic, difficult-to-treat localized variant of psoriasis that affects the palms and soles, significantly affecting patient's quality of life.
Read MoreEfficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris
February 2023 | Volume 22 | Issue 2 | Original Article | 197 | Copyright © February 2023
Calcipotriol, a vitamin D analogue is widely used in the treatment of psoriasis. However, poor adherence to topical therapy has led to an ineffective use of the medication and built a barrier to the t...
Read MoreThe Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
October 2022 | Volume 21 | Issue 10 | Original Article | 1070 | Copyright © October 2022
Background: Approximately 30% to 40% of alopecia areata (AA) patients have atopic dermatitis. Studies suggest that antihistamines and dupilumab may be effective treatments; however, t...
Read MoreEvolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care
October 2022 | Volume 21 | Issue 10 | Original Article | 1054 | Copyright © October 2022
Background: Despite considerable advances in our understanding of the pathogenesis and treatment of psoriasis, data pertaining to racial/ethnic variations, effects on barrier function...
Read MoreArtificial Intelligence in Hair and Nail Disorders
October 2022 | Volume 21 | Issue 10 | Original Article | 1049 | Copyright © October 2022
Artificial intelligence (AI), a field of computer science, aims at simulating human intelligence with computers. Though AI has surpassed dermatologists in skin cancer detection, it still lags behind v...
Read MoreDermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials
October 2022 | Volume 21 | Issue 10 | Original Article | 1084 | Copyright © October 2022
Background: Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for psoriasis treatment and...
Read MoreSystemic Medications Associated With Hair Texture Changes
September 2022 | Volume 21 | Issue 9 | Original Article | 989 | Copyright © September 2022
Background: In addition to hair loss, alterations in hair texture can be a worrisome side effect of certain medications yet are seldom reported and poorly characterized.
Read More Persistence With Biologic Treatments in Psoriasis: A Structured Literature Review of Studies Using Administrative Database and Clinical Registry Data
August 2022 | Volume 21 | Issue 8 | Original Article | 881 | Copyright © August 2022
Background: Psoriasis is a chronic, autoimmune-mediated inflammatory disorder. Drug persistence is a composite measure of effectiveness, safety, and treatment satisfaction, often esti...
Read MoreSevere Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
August 2022 | Volume 21 | Issue 8 | Case Reports | 897 | Copyright © August 2022
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of ...
Read MoreUnmet Needs in Psoriasis Patients
August 2022 | Volume 21 | Issue 8 | Original Article | 839 | Copyright © August 2022
Background: Psoriasis can greatly impact patients' quality of life. The introduction of new treatments has improved treatment outcomes, but treatment gaps may still exist.
Read More New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read More